Evidence map›Paper›PMID 32819443›Full record

ReviewMicrobial cell factories2020

Postbiotics-parabiotics: the new horizons in microbial biotherapy and functional foods.

Basavaprabhu H Nataraj, Syed Azmal Ali, Pradip V Behare, Hariom Yadav

Registry-linked trialAbstract readReview
In one paragraph

Review in Microbial cell factories, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07050485 (Postbiotics for Mitigation of Postoperative Dysbiosis in Gastrointestinal Cancer Surgery), which is not on this map. Cited by 298 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
298citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07050485 naenrolling by invitationnot on this mapstarted 2025, after this paper: background citation

Postbiotics for Mitigation of Postoperative Dysbiosis in Gastrointestinal Cancer Surgery: A Randomized, Single-blinded, Placebo-controlled Trial (REPOT)

TypeinterventionalSponsorUniversity of South FloridaRan2025 to 2026Enrolled30ConditionsColon Cancer, Gastrointestinal CancerArmsPoZibio, Inert placebo
3 · Its place in the literature

Who cites it

298 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Trial
  8. Effect of PostbioticNutrients · 2024
    Trial
  9. Trial
  10. Article
  11. Review
  12. Paraprobiotics Derived FromFood science & nutrition · 2026
    Article
  13. Review
  14. Review
  15. Development of Pharmabiotic Gel-Serums withGels (Basel, Switzerland) · 2026
    Article
  16. Review
  17. Review
  18. Review
  19. Article
  20. Article

238 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Basavaprabhu H NatarajTechnofunctional Starters Lab, National Collection of Dairy Cultures (NCDC), Dairy Microbiology Division, ICAR-National Dairy Research Institute, Karnal, Haryana, 132001, India.
Syed Azmal AliProteomics and Cell Biology Lab, Animal Biotechnology Center, ICAR-National Dairy Research Institute, Karnal, Haryana, 132001, India.
Pradip V BehareTechnofunctional Starters Lab, National Collection of Dairy Cultures (NCDC), Dairy Microbiology Division, ICAR-National Dairy Research Institute, Karnal, Haryana, 132001, India. pradip_behare@yahoo.com.
Hariom YadavDepartment of Internal Medicine-Molecular Medicine and Microbiology and Immunology, Wake Forest School of Medicine, Biotech Place, Room 2E-034, 575 North Patterson Ave, Winston-Salem, NC, 27101, USA. hyadav@wakehealth.edu.ORCID http://orcid.org/0000-0003-4504-1597

Funding

Wake Forest Claude D. Pepper OAIC - RenewalP30AG021332 · NIA · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI LEON LENCHIK · 2002 to 2026
$36.4M
Wake Forest Clinical and Translational Science AwardUL1TR001420 · NCATS · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI ARD, JAMY D, FOLEY, KRISTIE L · 2015 to 2023
$32.3M
Exercise Intolerance in Older HFPEF PatientsR01AG018915 · NIA · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI KITZMAN, DALANE W · 2001 to 2019
$5.2M
NCATS NIH HHS UL1 TR001420NIA NIH HHS P30 AG021332NIA NIH HHS R01 AG018915NIH HHS P30AG21332NIH HHS R01AG018915NIH HHS UL1TR001420
6 · The paper itself

Abstract

Probiotics have several health benefits by modulating gut microbiome; however, techno-functional limitations such as viability controls have hampered their full potential applications in the food and pharmaceutical sectors. Therefore, the focus is gradually shifting from viable probiotic bacteria towards non-viable paraprobiotics and/or probiotics derived biomolecules, so-called postbiotics. Paraprobiotics and postbiotics are the emerging concepts in the functional foods field because they impart an array of health-promoting properties. Although, these terms are not well defined, however, for time being these terms have been defined as here. The postbiotics are the complex mixture of metabolic products secreted by probiotics in cell-free supernatants such as enzymes, secreted proteins, short chain fatty acids, vitamins, secreted biosurfactants, amino acids, peptides, organic acids, etc. While, the paraprobiotics are the inactivated microbial cells of probiotics (intact or ruptured containing cell components such as peptidoglycans, teichoic acids, surface proteins, etc.) or crude cell extracts (i.e. with complex chemical composition)". However, in many instances postbiotics have been used for whole category of postbiotics and parabiotics. These elicit several advantages over probiotics like; (i) availability in their pure form, (ii) ease in production and storage, (iii) availability of production process for industrial-scale-up, (iv) specific mechanism of action, (v) better accessibility of Microbes Associated Molecular Pattern (MAMP) during recognition and interaction with Pattern Recognition Receptors (PRR) and (vi) more likely to trigger only the targeted responses by specific ligand-receptor interactions. The current review comprehensively summarizes and discussed various methodologies implied to extract, purify, and identification of paraprobiotic and postbiotic compounds and their potential health benefits.

Indexed as

Biological ProductsBiological TherapyInsurance BenefitsBacteriaFunctional FoodGastrointestinal MicrobiomeMicrobial ViabilityProbioticsBiological ProductsFunctional foodsHealth benefitsParaprobioticsPostbioticsProbiotics

Identifiers

PMID32819443
PMCPMC7441679

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.